Amundi
SGMO

Amundi’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Amundi’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,484
Closed -$19.2K – 2124
2023
Q1 		$19.2K Hold
11,484
– – ﹤0.01% 1965
2022
Q4 		$39.5K Hold
11,484
– – ﹤0.01% 1733
2022
Q3 		$57K Buy
+11,484
New +$59K ﹤0.01% 1648

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amundi's SGMO Position: Q2 2023 in Review

Amundi sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2023, closing a stake of 11,484 shares — an estimated $19.2K sold.

Amundi first reported a position in SGMO in Q3 2022 and held it in 3 quarters. The position peaked at $57K in Q3 2022. 152 funds tracked by Wall St. Rank hold SGMO as of Q2 2023.

  • Amundi reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2023 after selling out during the quarter.
  • Amundi sold 11,484 SANGAMO THERAPEUTICS INC shares in Q2 2023, an estimated $19.2K.
  • Amundi first reported a position in SANGAMO THERAPEUTICS INC in Q3 2022 and held it in 3 quarters.
  • Amundi's SANGAMO THERAPEUTICS INC position peaked at $57K in Q3 2022.
  • 152 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2023.

Based on Amundi's 13F filing for Q2 2023, filed 14 Aug 2023.